View clinical trials related to Healthy Subjects.
Filter by:This is a single ascending dose study of HSD-016 to provide the initial assessment of the safety, tolerability, how the drug is absorbed and eliminated, and its effect on the body.
Individuals who participate in regular physical exercise possess a lower prevalence of cardiovascular risk factors such as hypertension, type 2 diabetes, obesity and hypercholesterolemia, and aerobic exercise is therefore considered an important adjuvant therapy in risk factor modification and to promote health. The main focus of the present study is therefore to detect how rapid it is possible to increase aerobic capacity with interval running exercise. The hypothesis is that it is possible to improve maximal oxygen uptake faster when increasing training frequency. The total gain in maximal oxygen uptake will however be the same between the two groups when they have performed the same amount of training
A study in healthy volunteers to determine whether there is a drug interaction between GSK1349572 and tenofovir
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of ERB-257 in healthy subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of IV administered ERB-257 as single ascending doses to healthy Japanese male subjects
A Study to determine if a high-fat meal has an effect on the pharmacokinetics of bosutinib.
48 healthy adult male & female subjects will be enrolled in this study to determine the effect of Technosphere® Inhalation Powder (FDKP) on the QT interval of the EKG. Eligible subjects will be randomized into a dosing regimen after admission.
This study is to evaluate the effect of fluoride dentifrices on enamel with artificial caries lesions in an in situ model.
The purpose of this study is to evaluate the Pharmacokinetics (PK) and safety and tolerability of etanercept, 25 and 50 mg, administered as a single dose to healthy male Chinese subjects.
This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.